In The Crowded MRSA cSSSI Market, How Will Emerging Therapies Differentiate Themselves from Current Standard of Care?
Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important pathogen in complicated skin and skin structure infections (cSSSIs). Over the past 15 years, the MRSA cSSSI market has become highly competitive with new entrants typically restricted to later lines of therapy. However, given the large cSSSI patient population and achievability of high clinical efficacy rates, many developers seek to gain more rapid entry into the marketplace through regulatory approval in this indication. With an increasingly crowded market landscape, agents will need to differentiate themselves based on improvements in key drug efficacy, safety, and delivery attributes to capitalize on current areas of unmet need.